This module uses fundamental data of Galectin Therapeutics to approximate its Piotroski F score. Galectin Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Galectin Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Galectin Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Galectin Therapeutics Altman Z Score, Galectin Therapeutics Correlation, Galectin Therapeutics Valuation, as well as analyze Galectin Therapeutics Alpha and Beta and Galectin Therapeutics Hype Analysis.
At this time, Galectin Therapeutics' Short and Long Term Debt Total is comparatively stable compared to the past year. Net Debt is likely to gain to about 48.5 M in 2024, despite the fact that Debt To Equity is likely to grow to (1.13). At this time, Galectin Therapeutics' Capex To Depreciation is comparatively stable compared to the past year. Cash Per Share is likely to gain to 0.78 in 2024, despite the fact that Book Value Per Share is likely to grow to (0.95).
At this time, it appears that Galectin Therapeutics' Piotroski F Score is Very Weak. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Galectin Therapeutics is to make sure Galectin is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Galectin Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Galectin Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Galectin Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Galectin Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.95)
At this time, Galectin Therapeutics' Book Value Per Share is comparatively stable compared to the past year.
About Galectin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galectin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galectin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galectin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.